Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Lund, Sweden - 28 June 2024 - During June 2024, 675,300 employee stock options in Camurus' employee stock options program ESOP 2021/2024 have been exercised for subscription of the corresponding number of shares. In addition, in order to cover the costs for social security charges related to the program, 98,000 subscription warrants have been sold to Carnegie Investment Bank AB (publ), which has subsequently exercised all 98,000 subscription warrants for subscription of the corresponding number of shares.
To ensure that the company can fulfill its commitments under the long-term incentive program for employees of the Camurus group resolved by the 2024 Annual General Meeting (Performance Share Plan 2024/2027), Camurus has also issued 240,000 series C shares to Carnegie Investment Bank AB (publ) in June 2024. All series C shares have been repurchased by Camurus and converted into common shares in accordance with a conversion provision in the articles of association.
As a result of the exercises made under ESOP 2021/2024 and the series C share issue with subsequent repurchase and conversion made under Performance Share Plan 2024/2027, the number of shares and votes has increased by 1,013,300.
Prior to the exercise, the total number of shares in Camurus amounted to 57,623,618 corresponding to 57,623,618 votes. As of 28 June 2024, the total number of shares in Camurus amounts to 58,636,918 corresponding to 58,636,918 votes.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal[®] drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer, and endocrine disorders, developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
This information is information that Camurus AB is obliged to make public pursuant to Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act. The information was submitted for publication at 7:00 am CEST on 28 June 2024.